Holen Sie sich die Stockscreener-App
55.57
4.10%
2.19
Handel nachbörslich:
55.57
Schlusskurs vom Vortag:
$53.38
Offen:
$53.905
24-Stunden-Volumen:
1.72M
Relative Volume:
1.29
Marktkapitalisierung:
$5.30B
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-345.91M
KGV:
-12.74
EPS:
-4.3602
Netto-Cashflow:
$-280.51M
1W Leistung:
+0.91%
1M Leistung:
+24.67%
6M Leistung:
+52.16%
1J Leistung:
+59.23%
1-Tages-Spanne:
$53.91
$56.29
1-Wochen-Bereich:
$52.55
$56.66
52-Wochen-Spanne:
$26.74
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
55.57 | 5.09B | 7.50M | -345.91M | -280.51M | -4.3602 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward - MSN
Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why - MSN
Crude oil rises around 4%; Xenon Pharmaceuticals shares surge - MSN
(XENE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2026-03-22 04:08:37 - baoquankhu1.vn
Xenon Pharmaceuticals rallies after pivotal data shows major drop in monthly seizures - MSN
Xenon Pharmaceuticals stock faces pipeline scrutiny amid biotech sector volatility - AD HOC NEWS
Wolfe Research initiates coverage of Xenon Pharmaceuticals (XENE) with outperform recommendation - MSN
JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
XENE Technical Analysis & Stock Price Forecast - Intellectia AI
Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained - Bitget
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - The Globe and Mail
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE) Is Down 6.7% After Major Equity Raise Post X-TOLE2 DataHas The Bull Case Changed? - Sahm
Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win - Yahoo Finance
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 X TOLE2 Azetukalner Results - simplywall.st
XENE stock up as Azetukalner meets goal in focal onset seizures study - MSN
Jain Global LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Granahan Investment Management LLC - MarketBeat
Holocene Advisors LP Acquires 167,078 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Cinctive Capital Management LP Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Bamco Inc. NY - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
XENE: Wedbush Adjusts Target Price for Xenon Pharmaceuticals | X - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $63.00 by Analysts at Wedbush - MarketBeat
Wedbush lowers Xenon Pharmaceuticals stock price target to $63 - Investing.com
HighVista Strategies LLC Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
5 Stocks Making Huge Moves this Week - Insider Monkey
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward - Insider Monkey
Commodore Capital LP Has $108.41 Million Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Sets Date for 2026 Annual Shareholder Meeting - The Globe and Mail
Xenon Pharmaceuticals Inc. Announces 2026 Annual Meeting of Shareholders Details and Notice Procedures - Minichart
Christopher John Kenney Sells 1,410 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells $403,620.84 in Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Insider Andrea Difabio Sells 1,342 Shares - MarketBeat
XENE (NASDAQ: XENE) Rule 144 Notice — 3,750 RSUs Vesting - Stock Titan
Ian Mortimer sells 270,000 XENE shares; multiple disposals (NASDAQ: XENE) - Stock Titan
Xenon Pharmaceuticals closes $747.5M public offering By Investing.com - Investing.com Australia
Xenon Strengthens Balance Sheet With Major Equity Offering - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Finance Watch: As IPO Market Quiets Again, Xenon, Dianthus Price Big Follow-Ons - Citeline News & Insights
Xenon Pharmaceuticals (XENE) sets June 2, 2026 annual shareholder meeting and April 7 record date - Stock Titan
Xenon Pharmaceuticals closes $747.5M public offering - Investing.com Nigeria
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors - TipRanks
Xenon Pharmaceuticals closes US $747.5M public offering - Private Capital Journal
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge - Yahoo Finance
BofA raises Xenon Pharmaceuticals price target on trial success - Investing.com South Africa
BofA raises Xenon Pharmaceuticals price target on trial success By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Closes $747.5 Million Public Offering - marketscreener.com
Xenon Pharmaceuticals Nets $707.7 Million in $57 Share Offering With Pre-Funded Warrants - TradingView
Xenon Pharmaceuticals (NASDAQ: XENE) prices $707.7M equity raise - Stock Titan
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):